CalciMedica (CALC) grants CMO two stock warrants at $0.80 and $1.00
Rhea-AI Filing Summary
CalciMedica, Inc. (CALC) reported that Chief Medical Officer Sudarshan Hebbar received two warrant awards linked to a Securities Purchase Agreement dated June 23, 2026, with a June 25, 2026 closing, approved by an independent board committee. Each warrant covers 124,486 shares of Common Stock, one with a $0.8033 per-share exercise price expiring as early as December 25, 2027 and the other with a $1.00 exercise price expiring on June 25, 2031. Both become exercisable on or after August 19, 2026 and are subject to a beneficial ownership cap not exceeding 19.99%.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Hebbar Sudarshan
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrant F1, F2 | 124,486 | $0.00 | $0.00 |
| Grant/Award | Warrant F1, F3 | 124,486 | $0.00 | $0.00 |
Holdings After Transaction:
Warrant — 248,972 shares (Direct)
Footnotes (3)
- F1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
- F2. The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.
- F3. The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.
Key Figures
First warrant underlying shares: 124,486 shares
Second warrant underlying shares: 124,486 shares
First warrant exercise price: $0.8033 per share
+5 more
8 metrics
First warrant underlying shares
124,486 shares
Common Stock underlying warrant with $0.8033 exercise price granted to CMO
Second warrant underlying shares
124,486 shares
Common Stock underlying warrant with $1.00 exercise price granted to CMO
First warrant exercise price
$0.8033 per share
Exercise price of warrant expiring as early as December 25, 2027
Second warrant exercise price
$1.0000 per share
Exercise price of warrant expiring June 25, 2031
Beneficial ownership limitation
19.99%
Maximum beneficial ownership immediately following any warrant exercise
Securities Purchase Agreement date
June 23, 2026
Agreement under which the warrants and related securities were acquired
Closing date of Securities Purchase Agreement
June 25, 2026
Closing date for issuance of the reported securities
First warrant outside expiration date
December 25, 2027
Outside date for exercise, subject to earlier 30-day CM5480 IND clearance trigger
Key Terms
Securities Purchase Agreement, Investigational New Drug Application, beneficial ownership limitation, warrant
4 terms
Securities Purchase Agreement financial
"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Investigational New Drug Application medical
"following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S."
An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.
beneficial ownership limitation financial
"would exceed a specified beneficial ownership limitation, not to exceed 19.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
warrant financial
"The warrant may be exercised on or after August 19, 2026, and on or prior to"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
FAQ
What insider transaction did CALC report for Sudarshan Hebbar?
CalciMedica reported that Chief Medical Officer Sudarshan Hebbar received two warrant grants, each for 124,486 shares of Common Stock, as part of a Securities Purchase Agreement dated June 23, 2026, with a June 25, 2026 closing.
What are the exercise prices of the new CALC warrants granted to the CMO?
One warrant granted to the CMO has an exercise price of $0.8033 per share, and the second warrant has an exercise price of $1.00 per share, each covering 124,486 underlying shares of CalciMedica Common Stock.
When do the CALC warrants granted to Sudarshan Hebbar become exercisable and when do they expire?
Both warrants may be exercised on or after August 19, 2026. One expires on the earlier of December 25, 2027 or 30 days after public disclosure of CM5480 IND clearance, and the other expires on June 25, 2031.
What is the beneficial ownership limitation on the new CALC warrants?
Each warrant includes a beneficial ownership limitation so it cannot be exercised if, immediately after exercise, the holder’s beneficial ownership would exceed a specified cap, not to exceed 19.99% of CalciMedica’s Common Stock.
How were the new CALC warrants to the CMO approved?
The warrants were acquired from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, with a June 25, 2026 closing. The agreement and related security issuances were approved by an independent committee of the Board of Directors.
Are the reported CALC warrant transactions under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox was not marked as an affirmatively adopted plan, and the footnotes do not state that these warrant grants were made pursuant to a Rule 10b5-1 trading arrangement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
